Detalles de la búsqueda
1.
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
N Engl J Med
; 386(9): 847-860, 2022 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139271
2.
Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike.
PLoS Pathog
; 19(5): e1011308, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37126534
3.
A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study.
J Infect Dis
; 226(1): 109-118, 2022 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32604406
4.
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
Antimicrob Agents Chemother
; 66(3): e0170221, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34978890
5.
Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study.
Clin Infect Dis
; 71(10): e594-e603, 2020 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-32201897
6.
Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
J Infect Dis
; 219(7): 1026-1034, 2019 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30428049
7.
Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
J Med Virol
; 88(5): 798-806, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26412111
8.
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
J Antimicrob Chemother
; 69(4): 1090-7, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24284781
9.
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Nat Commun
; 15(1): 2175, 2024 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38467646
10.
Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study.
Antivir Ther
; 28(3): 13596535231174273, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37226302
11.
Towards Novel HIV-1 Serodiagnostic Tests without Vaccine-Induced Seroreactivity.
Microbiol Spectr
; 11(3): e0071523, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37222611
12.
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Res Sq
; 2023 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37398105
13.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Infect Dis
; 22(12): 1703-1715, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36113538
14.
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
Antimicrob Agents Chemother
; 55(6): 2872-9, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21464253
15.
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Antimicrob Agents Chemother
; 54(2): 718-27, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19933797
16.
Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.
HIV Clin Trials
; 11(4): 175-85, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20974573
17.
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
Nat Med
; 26(4): 498-501, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32235883
18.
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Antivir Ther
; 14(1): 103-9, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19320243
19.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet
; 370(9581): 29-38, 2007 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-17617270
20.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet
; 370(9581): 39-48, 2007 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-17617271